Methods: Four pyrosequencing assays were optimized and applied to the following loci:
Introduction
Currently, tuberculosis (TB) in Lebanon is highly affected by the Syrian crisis. Before the beginning of this crisis in 2011, the estimated prevalence of TB in Lebanon was 19 per 100,000 population. The Lebanese National Tuberculosis Programme (NTP) indicates that currently over half of the people referred to the NTP for investigations and treatment are non-Lebanese nationals [1] . As of August 2013, according to the NTP, 100 Syrian refugees have been diagnosed with TB in Lebanon, including 3 cases of multidrug-resistant TB (MDR-TB). of all TB forms were identified among Syrian nationals, representing 17% of all TB cases notified [1] . The NTP in Lebanon follows DOTS (Directly Observed Treatment Strategy), which has a high treatment success rate among Lebanese nationals. However, the treatment success rate is below that desired among the non-Lebanese patients due to their departure during the treatment [1] . MDR-TB, which is defined as being resistant to at least INH or RIF -the two most powerful first-line anti-TB treatment drugs -is emerging [2] . Weakened or disrupted services for the Syrian refugees can complicate diagnosis and treatment, potentially leading to an increase in MDR-TB. INH-resistant strains most commonly carry mutations on the katG gene, on the promoter region of the inhA gene and on the ahpC-oxyR intergenic region [3] . Mutations in several other genes may also lead to INH resistance, but are less common [4] . RIF-resistant strains serve as a surrogate marker for MDR-TB detection [5] . Resistance in RIF has been attributed to mutations within an 81-bp RRDR of the rpoB gene, corresponding to codons 509-533 [5] . Mutations outside of RRDR have also been reported, with a frequency of <2% [6] . Culture-based drug susceptibility testing (DST) may take 4 weeks from specimen collection to results. At present, pyrosequencing had become a novel approach used for the detection of TB infection and resistance. The objective of this study is to evaluate the pyrosequencing technology for the detection of MTB resistance to RIF and INH in the Syrian and Lebanese clinical strains.
Materials and methods

Bacterial strains
66 strains of MTB resistant to INH, among them 56 resistant also to RIF, were tested. These clinical isolates were provided by the Medical Biotechnology Section of the National Commission for Biotechnology in Syria and the health and environment microbiology laboratory at Azm Center for Research in Biotechnology at the Lebanese University between July 2003 and October 2005 [7, 8] . The drug resistance pattern of the Syrian samples was previously established according to the recommendations of the National Committee for Clinical Laboratory Standards [8] . Antibiotic susceptibility testing of the Lebanese strains was performed using a BBL TM MGIT TM (Mycobacteria Growth Indicator Tube) AST system (Becton Dickinson, Franklin Lakes, NJ), based on comparing the growth of the MTB strains in a drugcontaining tube with that of a drug-free tube [7] . All isolates were stored at 80°C. The reference strain H37Rv (ATCC 25177) was used as a control for the wild-type sequence.
Polymerase chain reaction
The primers used to amplify and sequence the katG gene, the promoter region of the inhA gene and the ahpC-oxyR intergenic region were synthesized according to Zhao et al. [9] , and those for RRDR were synthesized according to Bravo et al. [10] by ThermoScientific, USA ( Table 1) . Amplification of the target regions was performed in a thermal cycler (MyCycler C1000; Bio-Rad). The efficacy of the amplification was determined by gel electrophoresis. The polymerase chain reaction (PCR) products obtained from this step were used for pyrosequencing.
Pyrosequencing
Sample preparation for pyrosequencing was performed according to the manufacturer's instructions. Singlestranded DNA amplicons were prepared semi-automatically using a Table 1 ). The singlestranded DNA was annealed to the sequencing primer at 80°C for 2 min followed by incubation for 2 min at room temperature. The single-stranded PCR products were sequenced using the PyroMark TM Q96 ID System (Biotage). To identify point mutations, sequences from clinical isolates were compared with that of wild-type MTB ATCC 25177. An internal control was also used to validate the results.
Ethics approval
The research was approved by the responsible institutional ethics committee of the Lebanese University.
Results
For the INH resistance, the results (Table 2) showed that among the 66 isolates, 28 (42.4%), 14 (21.2%), and 6 (9%) had mutations on codon 315 of the katG gene, on the promoter region of the inhA gene and on the ahpC-oxyR intergenic region, respectively. The overall sensitivity for INH resistance detection by pyrosequencing is 72.6%. The most common katG mutation was Ser315Thr (92.8%). All inhA promoter region mutated strains had the À15 C-T mutation. For the ahpC-oxyR intergenic region, the most common mutation was 46 G-A (4 of 6 strains). Four strains had mutations in katG in addition to ahpc-oxyR mutations and 1 strain had both katG and inhA mutations.
Of the 56 RIF-resistant clinical isolates analyzed, all strains contained at least 1 non-synonymous codon change in the sequenced rpoB region (507-533) relative to the ATCC reference strain (Table 3 ). The pyrograms indicated the presence of 97 modified codons representing 34 different codon changes (Table 3) . One codon change was a consequence of a single base pair deletion. Five codon changes resulted in silent mutations through nucleotide substitutions, and the rest resulted in missense mutations. All silent mutations were accompanied by non-silent mutations. Codon changes occurred primarily at codons 531 (37/97: 38%), 533 (28/97: 29%) and 526 (9/97: 9%). The mutation S531 L (TCG/TTG) was by far the most frequent (35 patients: 35/56: 63%). Fig. 1 shows a representative DNA sequence analysis of 81-bp RRDR core region of rpoB gene of RIF-resistant isolates of MTB. 
Discussion
Pyrosequencing performs real-time sequencing of short DNA segments at a speed averaging 1 min per nucleotide. In this study, the pyrosequencing method was evaluated for MTB resistance detection; 66 clinical isolates resistant to INH were subjected to katG, inhA promoter region and ahpCoxyR intergenic region mutations detection, and 56 strains resistant to RIF were subjected to rpoB region (507-533) mutations detection. This study showed that the pyrosequencing applied to katG, inhA promoter and ahpC-oxyR intergenic region was able to detect a relatively large proportion of INH-resistant strains (72.6%). It is quite possible the presence of other mechanisms of resistance were mediated by the changes in other chromosome loci, e.g., kasA, dfrA and ndh [4] . The use of a single codon 315 katG mutation for INH resistance is not accurate in this country since it will lead to a sensitivity of only 42.4%. The prevalence of mutations in katG varies strongly among different regions of the world. The mutation rate was 98% in Russia [11] , 66.7% in Finland [12] , 60% in South Africa [13] and China [14] , 46% in Switzerland [15] and 37% in Italy [16] . To improve the sensitivity of pyrosequencing for INH detection, 2 loci (inhA promoter and ahpC-oxyR intergenic region) were added. In a study [17] conducted by Huang et al., 18 of 28 MDR-TB isolates possessed ahpC mutations alone or in addition to katG mutations outside of codon 315. Detection of INH resistance from these isolates was missed by the MTBDRplus assay; this demonstrated the significance of adding the ahpC locus for detecting INH resistance. The present study found a rather small increase (9.0%) in sensitivity contributed by ahpC. However, any increase in the detection of INH resistance reduces ineffective INH treatment and prophylaxis and is welcomed by clinicians. A recent study in the United States of America showed a sensitivity of 88.6% by using the 3 loci [18] .
RIF is a powerful drug used for treating TB. The accuracy of molecular testing for RIF resistance is critical, since it may influence early clinical decisions. The frequencies of mutations detected (100%) for rpoB in RIF-resistant isolates by the pyrosequencing assay are consistent with other reports in the literature and demonstrates the importance of the RRDR hotspot region in the resistance of clinical TB isolates. Several studies have indicated that this region is responsible for 90-95% of RIF-resistant cases [19] . Notably, the vast majority of patients (95%) had mutations in codons 531 and/or 533. This could greatly reduce the expense and complexity of future early detection efforts in the local patient pool. The present study also emphasizes the frequency of codon changes at position 533. In clear contrast to previous reports [20, 21] , the majority of isolates in this study exhibited more than 1 codon change (2) (3) (4) (5) . Many codon changes involved more than one base pair change. A significant portion appeared to involve a two-base pair inversion, while others were likely to involve multiple base pair substitutions through point mutations. The high GC/AT ratio may contribute mechanistically to the mutability of this hot spot region.
The main advantage of this assay is its rapidity compared with that of conventional testing. This characteristic, coupled with the excellent specificity for detection of resistance to the two most important anti-tuberculosis medications in the majority of cases, makes this assay potentially useful by allowing appropriate treatment several days or weeks sooner than would be possible with conventional testing. Pyrosequencing, however, still cannot supplant conventional phenotypic methods of resistance testing. 
basis for resistance has been identified, it should be possible to develop genotypic assays to detect resistance. However, practical considerations limit the numbers of assays that can be run for each sample, and costs and complexities of testing additional sites have to be weighed against the incremental benefits of such testing in clinical practice.
Conclusion
Pyrosequencing is a rapid and accurate method for detecting MTB resistance to RIF and INH. The accuracy of sequencing by pyrosequencing is comparable to that of Sanger sequencing, and the availability of sequence information enables users to study the association of drug minimum inhibitory concentrations (MICs) with each mutation. Once sufficient data associating specific mutations with MIC distributions have been accumulated, pyrosequencing may become a useful tool for predicting the level of drug resistance. Such information may help guide treatment decisions before the availability of phenotypic DST results. Based on the outcome of this study, a larger field trial of this assay is under way in Lebanon.
